XDR tuberculosis: A report from the New Delhi Tuberculosis Centre, India

Journal of the College of Physicians and Surgeons Pakistan

Volumn 19, Issue 2, 2009, Pages 133-135

  Dhingra, V K ^a,c   Malik, Sonia ^a   Hanif, M ^a   Arora, V K ^b  

^a New Delhi Tuberculosis Centre   (India)

^b SANTOSH MEDICAL COLLEGE   (India)

^c Santosh Medical College ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; THIOAMIDE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; DEATH; DISEASE SEVERITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS;

EID: 64149130612     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. CDC. Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs. Worldwide 2000-2004 MMWR 2006; 55:301-5.
2. World Health Organisation. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Weekly Epidemiol Record 2006; 81:430-2.
3. ZF Udwadia XDR-TB in India: When will we heed the alarm? J Assoc Phys India 2008; 56:409-10.
4. World Health Organisation. Anti-tuberculosis drug resistance in the world: 4th global report. WHO/HTM/TB/2008;394.
5. Canetti G, Froman S, Grosset J, Hauduroy P, Langerov'a M, Mahler HT, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-78.
6. Kam KM, Yip CW. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong-Kong, 1995-2002, after the implementation of DOTS-plus. Int J Tuberc Lung Dis 2004; 8:760-66.
7. Masjedi M, Farnia. P, Sorooch S, Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006; 43:841-7.
8. Jain S. High prevalence of XDR-TB from a tertiary care hospital in india (Session B98, Abstract No. 1398) American Thoracic Society Conference San-Francisco May 2007.
9. Mondal R, Jain A. Extensively drug resistant Mycobacterium tuberculosis. Emerg Infect Dis 2007; 13:1429-31.
10. Thomas A, Ramachandran R, Rehaman F, Jaggarajamma K, Santha T, Selvakumar N. Management of multi-drug resistance tuberculosis in the field: Tuberculosis Research Centre experience. Indian J Tuberc 2007; 54:117-24.
11. Gandhi NR, Moll A, Sturm AW. Extensively drug resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.